https://scholars.lib.ntu.edu.tw/handle/123456789/617146
標題: | A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma | 作者: | Lim H.Y. Heo J. Choi H.J. Lin C.-Y. Yoon J.-H. CHIUN HSU Rau K.-M. Poon R.T.P. Yeo W. Park J.-W. Tay M.H. Hsieh W.-S. Kappeler C. Rajagopalan P. Krissel H. Jeffers M. Yen C.-J. Tak W.Y. |
公開日期: | 2014 | 出版社: | American Association for Cancer Research Inc. | 卷: | 20 | 期: | 23 | 起(迄)頁: | 5976-5985 | 來源出版物: | Clinical Cancer Research | URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84918777261&doi=10.1158%2f1078-0432.CCR-13-3445&partnerID=40&md5=ce944a38d71e63767dc31015461398c3 https://scholars.lib.ntu.edu.tw/handle/123456789/617146 |
ISSN: | 1078-0432 | DOI: | 10.1158/1078-0432.CCR-13-3445 |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。